Apricus Biosciences, Inc. (APRI) Tops Q2 EPS by 9c

Apricus Biosciences, Inc. (Nasdaq: APRI) reported Q2 EPS of $0.05, $0.09 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $5.5 million versus the consensus estimate of $5.45 million.

For earnings history and earnings-related data on Apricus Biosciences, Inc. (APRI) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Jefferies upgrades Five Below to Buy, sees path to TJX-like re-rating
• Boxlight Corporation (BOXL) Tops Q2 EPS by 2050c